Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

At close: May 2 at 4:00:00 PM EDT ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Amicus Therapeutics FOLD is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Viking Therapeutics is developing drugs for obesity and non-alcoholic fatty liver disease. The company has no revenue and may have none for several years as it works to get drug approval.

Reserve your free spot now. TransCode Therapeutics, Inc. RNAZ announced further progress on Thursday in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. To date ...

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced some great news today, which is that it would be acquired by Novartis AG (NVS) for $7 per share in cash. However, there is room for additional ...